KZR - Kezar Life Sciences, Inc.
7.27
-0.025 -0.344%
Share volume: 90,760
Last Updated: 04-23-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.16%
PREVIOUS CLOSE
CHG
CHG%
$7.30
-0.03
0.00%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-09-2024 | 08-13-2024 | 11-12-2024 | 03-25-2025 | 05-13-2025 | 08-13-2025 | 11-12-2025 | 03-27-2026 | |
| Assets | |||||||||
| Total Assets | 199.130 M | 179.921 M | 164.086 M | 144.682 M | 125.260 M | 109.123 M | 97.726 M | 76.647 M | |
| Current Assets | 185.613 M | 167.617 M | 156.379 M | 137.488 M | 120.318 M | 104.702 M | 94.501 M | 75.732 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 520.000 K | |
| Short Term Investments | 146.766 M | 135.906 M | 113.530 M | 90.496 M | 77.359 M | 66.482 M | 51.281 M | 0.000 | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 33.032 M | 28.276 M | 34.858 M | 41.749 M | 37.002 M | 34.367 M | 38.935 M | 71.878 M | |
| Total Non-current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Property Plant Equipment | 3.652 M | 3.391 M | 3.149 M | 2.893 M | 2.650 M | 2.407 M | 2.175 M | 166.000 K | |
| Other Assets | 9.865 M | 8.913 M | 4.558 M | 4.301 M | 2.292 M | 2.014 M | 1.050 M | 749.000 K | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 199.130 M | 179.921 M | 164.086 M | 144.682 M | 125.260 M | 109.123 M | 97.726 M | 76.647 M | |
| Total liabilities | 30.009 M | 29.236 M | 30.037 M | 27.766 M | 22.191 M | 17.337 M | 14.750 M | 6.574 M | |
| Total current liabilities | 16.161 M | 17.495 M | 20.429 M | 20.329 M | 16.963 M | 14.365 M | 13.376 M | 6.574 M | |
| Accounts Payable | 5.059 M | 2.263 M | 3.461 M | 3.651 M | 1.966 M | 1.157 M | 911.000 K | 507.000 K | |
| Other liabilities | 5.019 M | 4.152 M | 3.259 M | 2.326 M | 1.354 M | 344.000 K | 0.000 | 0.000 | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 8.829 M | 7.589 M | 6.349 M | 5.111 M | 3.874 M | 2.628 M | 1.374 M | 0.000 | |
| Other liabilities | 5.019 M | 4.152 M | 3.259 M | 2.326 M | 1.354 M | 344.000 K | 0.000 | 0.000 | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 169.121 M | 150.685 M | 134.049 M | 116.916 M | 103.069 M | 91.786 M | 82.976 M | 70.073 M | |
| Common stock | 541.897 M | 545.038 M | 548.223 M | 551.577 M | 554.356 M | 556.812 M | 558.948 M | 560.605 M | |
| Retained earnings | -372.421 M | -393.968 M | -414.281 M | -434.499 M | -451.055 M | -464.759 M | -475.986 M | -490.532 M |